IDXG - Earnings call transcript Q3 2017 | Interpace Biosciences, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Good morning everyone. Thank you for joining us for the Interpace Diagnostics Conference Call to review the company's financial results and operations for the third quarter and year-to-date ended September 30, 2017, as well as recent developments. The news release detailing our results was issued and will be available on Interpace's website at http://www.interpacediagnostics.com.

Before we get started, during the course of this conference call, the company will make forward-looking statements. We caution you that any statement that is not a statement of historical fact is a forward-looking statement. the projections, about and plans, remarks prospects. includes company's expectations, financial beliefs This based analysis the to judgment date statements from cause on These are differ to and and that conference materially and actual results risks described of call as statements. are important subject in numerous those uncertainties could forward-looking the the of as XXXX, safe risks Interpace's release call are conference and in made this news with filings uncertainties These XX-Q periodic on today's August XX, XX-Q in public on associated harbor the XX, the today. quarterly quarter filed and for XX, on XXXX, XX, the March statements as ended in with with well the report on forward-looking on statement for XXXX, described quarter filed SEC, for the section the including the with Form quarterly September filed with and year ended XXXX, the Risk which SEC SEC June Form Form SEC SEC the XX, discussion the for XXXX, May was April the XXXX ended report the XX, amendment XX, company's quarterly December in on in on Factors filed report the our XX, filed quarter March company's XXXX, with the the Form XX-K XX-Q on XX-K/A the Form ended XXXX, the uncertainties undue shouldn't reliance risks, assumptions, be these and and other forward-looking on Because statements. of these placed

reason. forward-looking of statements revise any undertakes the to as press as no of for company any speak required statements update And these the maybe only publicly or In law, addition, except date release. by the obligation

in in and the release, supplemental website. table included reconciling on company company's information. non-GAAP that also addition A numbers which information non-GAAP historical GAAP provide performance. our helpful the to future believes numbers, information company provided to has non-GAAP is the assessing and The available In the the is supplement, these information meaningful are in GAAP earnings

over call and to of the Executive turn Officer Diagnostics. to like would Interpace Chief President Jack I Now Stover,

Jack Stover

Early, joining Paul, third year-to-date us and September you, our for our performance on review an a open Thank results that for is questions. you Chief we XX, period with progress the update XXXX. and then today today Thank for our the ended begin will review the good I our call of call morning to-date, we Officer. following me Financial With will financial will for everyone. quarter

As I you me let typically do, our remind overall of mission.

by pathology integrated commercial and personalized better medicine to We in improved provides company leveraging latest patient and decisions tests clinical evaluate diagnostic fully are of for informed risk a services molecular technology cancer that the management. and

we of commercially one used DNA rule Esophagus and reminder, currently is as into the fourth BarreGEN one believe second-long characterizing diagnostic thyroid cysts. gather the with that solution. rapidly well cancer. physicians ThyraMIR available data first know to the evaluation is of process as clinical expression esophageal panel continue for information. As may carcinoma. single improves CEP. test, testing the a pre-operative allow a our have key only PancraGEN with of as physicians using combination launch providing identify has micro in people providing new for a diagnosis fingerprint important will biology. tumor product on X tests addition a assay, growing to diagnostics classifier as is new cancer reimbursement indeterminate over US commercial gene ThyraMIR to a greater RespriDX, what the service to in opinion this for in pancreatic or nodules. ThyGenX a markers sequencing RespriDX we confidence next of out affects Barrett's assessment that nodule our nodules thyroid rule tumor accuracy and thyroid XX PancraGEN tests leaders a test being And additional time many for is and ThyGenX superior brief of for with diagnostic first accurately specificity as molecular insight thyroid assist soft generation us two and Esophagus clinical with on we of favorable cancer these over million microRNA is primary more either genomic When progress ability with compares to surgeries. is seeking unnecessary is in risk you the Barrett's the with or in assay now intent cancer lung a the by that required the the four that in can test test lung of metastatic avoid evaluation our market nodules molecular US to

Now us year putting third Interpace the were Record of pro-forma for quarter annual of XXXX. quarter. in reported prior over back million. net announce rate to of pleased all quarter to well million, on X.X on revenue $XX the increase XX% run I'm third the the performed fronts a revenues approximately net

year-to-date and Florida. period have both the our is been damage rebuilding both seen important cautiously XXXX. and hurricane franchises. important our was also improvement our third Texas as and respectively volumes resources that several even in reduction efforts markets to in particularly for key This year-to-date, loss early XX% the I'm in a test considering pleased over cut including Endocrine cost GI we quarter announce in and and that XX% net our grew we quarter Our for of back the prior-year

commercial the of of net million. revenues their Additionally, third and I in $X applaud the efforts. fourth team represent quarter net excess quarter our for revenues quarter net revenues sequential straight first of growth

aggressiveness QX, the such month. we've ever to we a most And of the TERT processed. the test July. may our XXX of been month announced marker You addition August, have that assays in in we over remember of inbound In the thyroid in recorded collected single alone cash

Code September, as for we the announced quarter it services. Approximately also And good Coverage increase our important us PLA of reimbursement covered October, would Medicare we in Health announced of to is very our in But In easier by ThyraMIR. get a agreement sigma's XX% the XX% announced for ThyGenX making In well. for announced for us. assay the reimbursement paved new August, important January several has been our XXXX. our that AMA that signed reimbursement had it's July, ThyraMIR CMS of we cover by In Medicare. business So, Oxford we quarter a ThyGenX ThyraMIR. X, beginning to announcements

during believe XXXX LabCorp the quarter ThyraMIR announced When including our Healthcare are contract our thyroid our multi-year of for expansion assays future Coverage national well of accomplishments our in recent also agreement We United our you products. our to renewal the announced plans. our support York to year-to-date our as reimbursement positioned we April, State Aetna for and with thyroid well consider market New growth products, we as approval

launch importantly of are GI PancraGEN and we platform the RespriDX. cancer and our on that is about encouraged assay, new our RespriDX identifying we primary has at biopsies Additionally, other products. and targeted already lung in PathFinder built versus metastatic lung use

MAC, local by commercial Importantly, RespriDX plans. Novitas, is most and covered Medicare our as

we Needless favorably at a study dedicated BarreGEN assay. of of treating we LOH and ACOG were related our a are October the marketplace. announced clinical our or on has to by critical, packed we we manager excited results, We PancraGEN and October the of have for us to And and product presented Supporting Loss the this development diagnostics the diagnosing hired to two in enhancing initial publications presented worked in in benefits are company which for Heterozygosity our to about that ThyGenX impacting interest any pleased with prospects. with the is to patients. room related adding say, who

tell in improve as more detail. Jim our and will continue also you sheet We to liquidity, balance

XX.X Our of million. our was at stockholder's in equity cash million was position September XX XX and excess

With Our was for of cash the second I like Jim? over recently X to highlights quarter more our turn financial in Early, to million. detail Jim [ph] CFO and as the call November the to year-to-date. would that position more discuss $XX.X

Jim Early

Jack our to financial statements. and elements Today Thank morning, you, in the good on focus I'd everyone. key

third increase for as the excess period over increase X the million, X% of XXXX quarter. revenue as prior $X.X well net year was prior of the said, Jack for million quarter over time As at a comparable which XX% the a the first of in was

revenue principal reason net The XX% compared million growth our XX.X for in was reimbursement year-to-date X.XX Our to revenue was increase. prior year, million our and both growth improvement. the thyroid net in franchise units or endocrine

test We our or to a sales growth also gastrointestinal pancreas smaller extent. and experienced unit net in

industry, GAAP, as may standard. which and revenues know the still it accounted for much at of Therefore, reimbursement. with to revenue a As of cash Beginning Board adopting accounting standards accrual are accrual the the our new on of to required also referred all require as record well accordance with in developing an of that a net net payers while XXXX, the very impact XXX, ASC you basis track report difficult adopt evaluating like our between and known us accounting. differential the standard you revenue we are it because broad realize, we is recognition to many effectively is further in is Standards will on A project is Accounting revenue from Financial cash competitors current might basis. timing of a expanding new to currently reaching. We're times our in

in cost the of prior marketing the amounted X.X as to costs million expanded expenses. net reagent to XXXX. the and X.X and an and in revenue G&A from year-to-date for and period as a cost the X.X million, cost the profit same reason respectively amounted of profit year-to-date compared change cost of the of million increase our force X.X million sales year-to-date a compared was a third activity. compared marketing and gross in prior-year of bad were as period due million to G&A, gross prior general for really million legal increased for to XX% of quarter to same the X.X costs year. period. and and period due to to have the debt the XX% that reduction XXXX, XX% reduction Sales of XX% X.X Sales sales. comparable period to Our million, year, timing X.X from for for The million we principal of and administrative same retards amounted quarter quarter X.X to marketing of as same the the was

headcount year currently Our to compared end. XX is at XX as

contingent quarter RedPath That to reasons XXXX. and for While of months to the during million royalty XXXX. incurred impairment us we related comparable acquired value same we determine equity the XXXX first third XXXX as principally X.X the to XXXX, our X.X million quarter to year-to-date Accordingly, quarter as X.X of the obligations million XXXX value no year or with of was the XXXX. assay of charges last in the net no charge quarter net of in net a write-down X.X of of first compared in reported of ended the taken benefit the consideration XXXX million that we shareholders. debt assay loss for contingent the of for September of charge of the had for terminating assays changes was above. million to period consideration in was have a million fair to the related operating third acquisition was of loss third during quarter X.X value due mentioned impairment of The with year. assay operating two compared of write-down We previously of in fair noted milestone million as prior change had to XX, X.X in the Then the three quarter X.X a for associated extinguishment the the the

year-to-date quarter In was for XXXX the adjusted our as loss long-term directors adjusted year-to-date from for performance, was X.X and XXXX. you present related to as and for loss an was six operations short a management reconcile million as to to negative extinguishment debt third the X.X EBITDA as the company's million our XX, write-down. loss for Accordingly, September taxes, earnings amortization demonstrate the year. XXXX XXXX board net interest, net Included continuing depreciation or negative the the million we million charge X.X Our assay effort XX, loss XX.X well X.X to quarter ended million before the prior compared of to million ended our months compared EBITDA. for how of in evaluates the to of in in and September X.X our

with principally negative to to million X.X assays continuing adjusted period improvement last due year period million million in operations. XXXX as loss Total XX.X XX, to increased in to for from to to have over Our the raises, EBITDA year, the million and million capital with XXXX repayment million ended XXXX. and from nine-month these total September consideration at And our equity, XXXX of was from the of conjunction XX.X equity at conversions year-end compared XX.X compared decreased the liabilities September same reductions the capital as negotiated of end and negative elimination XXXX obligations raises, reduction of $XX X.X end. in million at XXXX XX, sincere operations stockholders' contingent settlements. rose our of debt X.X debt and In

in our by recent of to cash of due let million, November the that burn proceeds back Our you net the cash million excess me up With Jack raises the the on our from quarter call to was end X.X principally our XXXX XX.X position turn million. as X to at position amounted Jack. and capital said, of offset XX.X at previously year-end

Jack Stover

couple A items guarantee Jim. listeners the up value especially over additional our of our to these believe thyroid Number franchise will should of the that occur. obviously the several in consider, success for drivers term. could be each although in that ramping have our near reimbursement Thanks a we be things we can't recognized one, near we term potential

As that additional adding excited three, about Number to evaluation provide of or terms assay, marker our growth if assay. thyroid a us. in I aggressiveness in our of improvement new TERT for interest we're the the will Heterozygosity could Of you Loss LOH mentioned, of

PancraGEN as doing the force sales of of possible York gen expanded sequencing advantage We lesions next migrating our our reductions of reimbursement and thyroid solid state we're PancraGEN approval take on market also of of focus process that. pancreas and for bile assay our the well in and to as assays. duct expanded improvement to to New addressable especially cost of We related our a

with And the forward potentially looking are back as large this around partnership are call will product have LabCorp our opportunity for I thyroid a the on very expanding operator our We now to further to essays. to turn exclusive accelerate we strategic important yet. BarreGEN our focusing of relationship nothing market of lastly, we report although to Q&A.

Operator

we'll take from And question Yi Wainwright. Instructions] from [Operator a Chen H.C.

Yi Chen

in question is, first faster offerings expect fourth quarters? which do among My test the the your growth you to see

Jack Stover

be look you how assay quarters see reason grown we'll been and but quick. I several reimbursement principal that we I growth at assay that really have think last that's greatest in and that's the the the best growth thyroid the the think the in certainly the depending is, has for that's the also that on product growth, calculate as dollar we in the will likely

we'll grow think continue to I that in space.

Yi Chen

there expect a how is in question is an and long is, and you accounting for much any change how XXXX, crew the second reimbursement start due current of impact you My cycle, margin. topline once gross revenue on

Jack Stover

making We're the that of in evaluation. process still

terms in timing. any don't have really specifics we of So,

it fact, you those reimbursement different. break reimbursement, are Medicare products, very across the basically product across timeframe for the versus different And timeframes private for If look and in is at into our line. reimbursement

then a difficult for a - So, an result plan us being equity to additional revenue revenue to all have opening change it's will of like will and project adjustment this be. as as we prospectively just of you we be in accrual difficult accounting having reporting impact a our can't kind the providing terms fact X All where that is in guidance said, at our say of even impact to-date know we've beginning that it's of that don't a there it that and upon just basis. is we revenue confirm seen positive All be in I January on positive course is finished time. can of positive without will this know based it what impact, an that

Yi Chen

Last within add months. to sales do team to expect question next additional the is, you the reps XX

Jack Stover

increase basis. likely rep had been answer this annual year, the do to XXXX what we added The And an based success Typically, well. around has we've is in that that yes. upon as XX% we'll on

Operator

comes Goovaerts question Pierre from BioMedwaregroup. next of Dr. Our

Pierre Goovaerts

first for dependent you mentioned as questions the one, on three heavily you, particularly past, and company and enforcing have of in have intellectual the patents. is the property success obtaining I

property. in XXXX, that April related for intellectual stating that granted to cover Rosetta currently that letter ThyraMIR gene in expected be Rosetta you actually so, Genomics you regarding would any to shortly And general, And receive a Could classifier. update from patent an expression you involved this procedure? provide are litigation in

Jack Stover

me first, involved Let question litigation answer the we're intellectual related property, I no, so. and in second is think the answer don't any that not

disclosed the relates from that Second considered Rosetta, of we've as to carefully. have letter that it very all, we

in Rosetta. have with We discussions been

in necessarily know is patents or you always protection. not this and space, intellectual As patent by property driven

but feel we protection companies very And come that attorneys good with only intellectual of freedom protection patent. again, to I a it's them our Our or operate look other the the make without have with around have to algorithm the our think to expansion, companies we patents, and as the work other et comfortable, molecular attorneys by feel very cetera. speak. patents to Rosetta comfortable diagnostic part horizon of most patent ability as property And at those patents from so knowhow

Pierre Goovaerts

also the relates competitors as know but tests have know, lower introduced you that competition. market. currently what by given a sensitivity has advantage But to source the which both the BarreGEN. the what revenue again your and a similar second of or general, about BarreGEN in for the would for substantial and and been term changer concern be, Do My would dollar game close FISH NeoSITE the you being testing be potential it's game changer BarreGEN, question I the know potential any of the I what in be billion know regarding example to available of than available is company on but specificity deployed regarding market? is the I test Panel, [indiscernible] molecular

Jack Stover

I guess a on that. couple of comments or remarks

all, opportunity we or evaluation. there as mentioned that is believe in for variety of of believe room different that plenty it's along market continuum market very significant We First you assays the of tests size. a of a

emerging, transition of there of to the we're you're is being certainly that lot the And really business, aware share a to aren't but competitors in of able As the competitors today market market it, kind are key look Esophagus it's of us. matter that the right. we or certainly gaining the Barrett's fact

the take mostly BarreGEN, look very you difficulty If a in sampling did a good, look at relatively small of we study results patients, clinical of the because a samples. less small XX than remember garnering they but relatively that clinical it's or

that So, we screening. partners other market opportunity big reasons a can seeking especially need one us we're work other being said, they to partners, conjunction test that's the and space. in the likely expand and is All future before, this said why in Barrett's device that we've of the in with in

also of we that are the with opportunities see the in concert advantage We screening assays other space take that Barrett's do. that other much in very can than smaller we

Pierre Goovaerts

public price investing then a the And retail company than share X% shares, March warrants. concern repeated course my been since dilutions the last more is quick company think the offerings is, the and have of and XXXX I I've as of and by from I been own in investor, hit private or our

early than when like want was to October dumped, and warrants I some see frustrating for some the and $X.X dropped down grands long-term old hundred is still new share you to me. very one point short-term issued, gains. finally basically which investor from were ones breaking more were a Because And was rated and $X.X, price even I

the sell and of stock and for you because to down. that, a just back drop be to its so, on back, you basically that [indiscernible] price And wait

stock stock the investors odd to through in to anything if invest who listening investors mentioned not a be manipulated is big are confidence shareholder playing institutional During able only to usually gains are So, not think company public that say it's obtained remediate more private want attract great company, in try a penny who you been their lost the a sorted, have is additional you think situation? heavily should I to which offerings. with great problem the don't meeting you no warrants, stocks, any future, because you and price. who with has How the stocks. but to to I and funding the Do the issue

Jack Stover

to annual quarter. PDI, to and of fourth company Sure, there in about that address quarter, that gotten happy as of meeting that were Interpace little spin-off obligations of we've we transition had. the a that's that the talk Interpace turn good I'd we out the lot you're news did well basically us as be lot those of PDI was transitioned a number most we from mechanics behind look of about a bit right are a the it through obligations host it, at But as of at obligations one. The is stock, the Interpace. that third

the and that, with is excess other that some The sitting with we've November conversions warrant release included reason the X. as $XX.X of million of in we're in of the had, we this that is

exercised a warrants are really the a that the view. first still We year warrants point in comfortable combination are of warrants some cash half and view, have So cash we're a fact in some the outstanding outstanding, last point very half, can the feeling a that. to from for and us. position a a $X.XX we're last $X.XX comfortable time of in in in of the or that year for and bringing additional But from cash about $X.XX very be time first

In also of rebuild operating addition our it us some to to activity. that, allows

opportunity we would All million. raise think I would X.X very won't the August that doesn't Meaning how we to being or we might able in raise mentioned, have actually situation here where in future, balance Difficulty]. may at transaction be I we sit inbound future month we product capital, inbound a we be mean with excess and cash was that that our ever that we we money different. raise potential in of as additional in cash have from [Technical actually money today cash it satisfy As an we're the but said, that the seeing with a the greatest the at utilizing look operations. X.X acquisitions million the but as particular cash be And and

past a we time being in spend third first concerned worrying having is report cash cash and quarter here position. we're think say lot I'd that the quite time of with the about and comfortable sufficient the I our in So, for the

Pierre Goovaerts

reason you acquisitions you were or I and to to Where establish you soon, a such the most footage a on planning mentioning able is there warrants. any you in to be need a it money any cash. is partnerships acquisition having be hurry to to have you times, recent you these by know, you few need been strong all so exercise why for, need money mean, are

Jack Stover

position. Yeah, we are in a very positive

We acquisitions products. are looking at of any potential

certainly is that is think those position opportunities And seeing we're a that the balance of to of to a lot stronger our reasons able sheet acquisition potential products. on I we're so, a in be execute one and

So that's one. number

point I best grow we other timing fashion. business driving and and no this a the the really a that's of there's view, think expectation to can timing that than need as requirement comparable from

substantive nice in. to and in in $XX company that critical to grow revenue mass say even space reach it but as that's that way another to So, potential hear, million to need we be certainly that we're revenue the a base even to larger is

keenly So, that. of aware we're

Pierre Goovaerts

this need to money money, you type to spend you that understand know I particularly of Now business. earn in

Operator

McCarthy question from next Maxim of Our Group. comes Jason

Jason McCarthy

expect that one the how which hit A the that first is, Can to had you the revenues that over CMS, see test half a topline. going related that adoption detail marker and TERT values couple more came in role discuss to of versus 'XX how looking other question you Can could in reimbursement. changes increase for could a first so of test the And you the little reimbursement the that there? tests have available physician the bit doctors it the the the rather and or discuss predictive clinical in changes year one next are I far thyroid a think potential used or to forward. my play in questions, clinical you it significant bit at just driving in going you that play out in mentioned marker, how that's that

Jack Stover

first, improvement. question basically in relatively your reimbursement. reimbursement The a of position been Let I on the CMS me announcement the putting referred much in answer again support one side, really to reimbursement, terms broad-based ThyGenX Medicare changes some us of there's with stronger our first a on that was in and XX%

based. our XX% that is our If you that look at a look of ThyraMIR assay, of units basically volume of and really convert remember of you to in really about Medicare ThyGenX, ThyGenX XX% and and assay, at our or ThyGenX combination assays revenues kind But ThyraMIR. ThyGenX that

potential saying January you're X. ThyGenX's substantial a is change as pretty reimbursement in what So, of

and it XX-XX basically different it's if ThyGenX you slightly look at way you If combined look you in wholesale and a ThyraMIR you excess as at split. $X,XXX will price look and it from might a of the at of

assays of new those that of expect what be is are of We and Also, covered XX% basically related really with that are a under and not that the of in improvement this to and to something half portion certainly ThyGenX in be to able now, able we reimbursement. we mechanically number not will that be So, that have would code covered determine is ThyGenX CMS. a yet. see to the

the well. XXXX; out don't that revenue We for is yet what it. of there there's we're know new So, as on expectation certainly working

I what's as that, and Being to And they will as or TERT evaluated able TERT it positive a we've TERT this and to recognized interest have is if insight to assay. marker is really a if it issue we're and recognized unique interesting terms ThyGenX ThyraMIR aggressiveness. think assay strong have as you you recognized of I without physicians what in marker negative And aggressiveness. down beyond certainly kind into is it a now is way because believe our about of our gives important. most allows physician marker losing drill into of build kind the predictive of and is And perhaps the driven seeing any of our other will the well of On believe we of recognize think value, quality as components them assay of a in TERT. TERT that aggressiveness, the that the that we the of we understood well such is uptick

Operator

[indiscernible]. Instructions] [Operator The next comes question from

Unidentified Analyst

balance the the and Great I think the but right the My debt answered concern going numbers you direction. free all was patents, sheet that. quarter, seeing loved Rosetta in

your that to numbers; to think price it these no them. as more attorneys and [indiscernible] with comfortable need I hearing think these of the types purchase positively analysts are will work I arounds here coming it are just buying January want the numbers those prior outstanding. stock. comments analyzed could effect see and was I into which great think to But I quarter, make to from I that's react

Jack Stover

is awareness I Patrick, it's the awareness think and you thank about and Interpace I our is growing. that, an other thing think issue

by as I'm encouraged So, well. certainly that

Operator

open, Veitch of Veitch next please Morgan go Mr. your ahead. Our question from Stanley. comes David line is

Companies. RedChip next from Singh of question Our comes Suraj

Suraj Singh

discuss question. on model How my you test? your perception it market as for does thyroid think lung And the have test. new cancer were I I just a reimbursement the same can all is questions also, quick the answered. the it, follow

Jack Stover

Yes, market question. the be to good quite encouraging. a early thanks seems interest Suraj Yeah,

on sales and But we feedback is going on. we're very limited positive. marketing so, going the have getting And

well, combined is the excess thyroid the assays $X,XXX. for excess our it's thyroid our assay our in of assay PancraGEN reimbursement lung in of and even fact, In as around assay,

market should know, you well in general it's, lung since many in a a for mention also product as I from And which already view, potential commercial especially to have of potential, is component growth we in the opportunity our Medicare is any product. good from point have as important carriers. also very reimbursement it's of So, revenue this that guidelines, assay a us

Operator

David comes [Operator from our Instructions] more from Veitch Once question Stanley. Morgan

David Veitch

for not accumulate money. investor take money to the is and to you with that someone regarding wonderful sheet, your it your has buy cash, in Maxim comment banker Is your on the and do come relationship your Based substantial on market cap with addressed much balance My of question would a awareness your could half in them? topic that about you marketplace. basically still and with of position you've

Jack Stover

They and a with situations, of capital. helped not in raising terms just closely We around Maxim. market worked of work us different have variety

David Veitch

Are there up calendars? meetings any other that conferences set the in or our could we investor put near in future

Jack Stover

more We've we'll The coming working answer right the but here They bunches. of on in up. is terms those Actually, yes. on there now, put come website been pretty so shortly. we're active are in investor conferences, actually those

I think was last did one Dawson we the James.

them that is in broadcasting the presentations, have we is to something maybe other tended same The ought the future we not at consider to those but broadcast that's time.

Operator

have It are closing any at this appears time, you Jack questions remarks. there do no further

Jack Stover

with again, hope We're in the and believe for things many A I is apart our the say your endocrine thing time franchises never our that and but We're joining couple and of results, all commercial along few quarter pleased foremost over demonstrate we're our developments we're from should of forward very many sets year-to-date exciting We first One satisfied. this fully competitors. remember with to in for are on today and our improved continued we explore that and GI that integrated support. obviously months you next our pleased company two and you growth a thank lung major cancer, The our this management. to updating our are we mention, progress. especially to and RespriDX. all third also look us us I call And we we effectively. liquidity think allows cost go about product and rational very to which options. And sheet excited various launch balance pleased with together

Operator

you This concludes for participation. today's your Thank call.

You may now disconnect.

Interpace Biosciences (IDXG) 13 Nov 172017 Q3 Earnings call transcript